Ipsen Biopharm Limited

Akagera Medicines, Inc.

Merrimack Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc.

Sutter West Bay Hospitals

Sutter West Bay Hospital

Hermes Biosciences, Inc.

Ispen Biopharm Ltd.

Ipsen Biopharma Ltd.

Immunyx Pharma Ltd.

Daryl C Drummond

Dmitri B Kirpotin

Keelung Hong

Mark Eamon Hayes

Alexander Koshkaryev

Charles Noble

Suresh K Tipparaju

Victor Mandla Moyo

Jonathan Basil Fitzgerald

Bolin Geng

Ozan Alkan

Sarah F Blanchette

Douglas J Moore

Andrew J O'Brien

Kevin Kesper

Antoine M Awad

Thomas Joseph Wickham

Samuel V Agresta

Bart S Hendriks

Helen Lee

Daniel F Gaddy

Ross B Fulton

Wei Wen Zheng

Wei-Wen Zheng

Seth Jonah Salpeter

Samuel Agresta

Thomas Wickham

Dmitiri B Kirpotin

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a neutrophil-associated disease or condition in a subject in need thereof are also provided.

Neutrophil exocytosis inhibitors

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof

The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.

Ionizable cationic lipids

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

Stabilizing camptothecin pharmaceutical compositions

Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.

Combination therapy for cancer treatment

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Liposomes useful for drug delivery

Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)

Growing community of inventors

Lincoln, MA, United States of America

Daryl C Drummond